Fulgent Genetics (FLGT) EBIT Margin (2015 - 2026)

Fulgent Genetics has disclosed EBIT Margin across 12 years of filings, most recently posting 48.67% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 48.67%, down 2172.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 29.56% (down 497.0% YoY), and the FY2025 annual result was 4.56%, up 2152.0% from the prior year.
• EBIT Margin came in at 48.67% for Q1 2026 at Fulgent Genetics, up from 125.0% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 63.05% in Q1 2022 to a low of 214.34% in Q4 2023.
• The 5-year median for EBIT Margin is 25.36% (2024), against an average of 34.72%.
• Across the five-year window, EBIT Margin jumped 19317 bps in 2024 and slumped 10383 bps in 2025, its largest moves.
• Fulgent Genetics' EBIT Margin stood at 0.33% in 2022, then sank by 64436 bps to 214.34% in 2023, then surged by 90 bps to 21.17% in 2024, then slumped by 490 bps to 125.0% in 2025, then soared by 61 bps to 48.67% in 2026.
• The last three EBIT Margin figures came in at 48.67% (Q1 2026), 125.0% (Q4 2025), and 18.26% (Q3 2025), per Business Quant data.